MX343328B - Analisis para la deteccion de farmacos anti-tnf y anticuerpos. - Google Patents

Analisis para la deteccion de farmacos anti-tnf y anticuerpos.

Info

Publication number
MX343328B
MX343328B MX2014002586A MX2014002586A MX343328B MX 343328 B MX343328 B MX 343328B MX 2014002586 A MX2014002586 A MX 2014002586A MX 2014002586 A MX2014002586 A MX 2014002586A MX 343328 B MX343328 B MX 343328B
Authority
MX
Mexico
Prior art keywords
autoantibodies
assays
detection
tnf drugs
level
Prior art date
Application number
MX2014002586A
Other languages
English (en)
Inventor
Sharat Singh
Shui Long Wang
Linda Ohrmund
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX343328B publication Critical patent/MX343328B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La presente invención se refiere a análisis para detectar y medir la presencia o nivel de terapéuticos y autoanticuerpos de fármaco anti-TNFa en una muestra. La presente invención es útil para optimizar la terapia y monitoreo de pacientes que reciben terapéuticos de fármaco anti-TNFa para detectar la presencia o nivel de autoanticuerpos (por ejemplo, HACA y/o HAHA) contra el fármaco.
MX2014002586A 2009-10-26 2010-10-26 Analisis para la deteccion de farmacos anti-tnf y anticuerpos. MX343328B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US25504809P 2009-10-26 2009-10-26
US26287709P 2009-11-19 2009-11-19
US32463510P 2010-04-15 2010-04-15
US34556710P 2010-05-17 2010-05-17
US35126910P 2010-06-03 2010-06-03
US38967210P 2010-10-04 2010-10-04
US39358110P 2010-10-15 2010-10-15
PCT/US2010/054125 WO2011056590A1 (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies

Publications (1)

Publication Number Publication Date
MX343328B true MX343328B (es) 2016-11-01

Family

ID=43618083

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012004877A MX2012004877A (es) 2009-10-26 2010-10-26 Analisis para la deteccion de farmacos anti-tnf y autoanticuerpos.
MX2014002586A MX343328B (es) 2009-10-26 2010-10-26 Analisis para la deteccion de farmacos anti-tnf y anticuerpos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012004877A MX2012004877A (es) 2009-10-26 2010-10-26 Analisis para la deteccion de farmacos anti-tnf y autoanticuerpos.

Country Status (15)

Country Link
US (5) US8574855B2 (es)
EP (1) EP2494352B1 (es)
JP (3) JP5697677B2 (es)
KR (2) KR101881714B1 (es)
CN (2) CN102695955B (es)
AU (4) AU2010315547C1 (es)
BR (1) BR112012009855A2 (es)
CA (2) CA3108458A1 (es)
ES (1) ES2796530T3 (es)
IL (2) IL219315B (es)
MX (2) MX2012004877A (es)
NZ (3) NZ599456A (es)
RU (2) RU2015148676A (es)
WO (1) WO2011056590A1 (es)
ZA (2) ZA201203717B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261230B1 (en) 2002-09-11 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Protein purification method
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RU2015148676A (ru) 2009-10-26 2019-01-15 Нестек С.А. Способы выявления препаратов и аутоантител против tnf
SG189391A1 (en) 2010-10-18 2013-05-31 Nestec Sa Methods for determining anti-drug antibody isotypes
CN103502815B (zh) 2011-02-17 2015-09-23 雀巢产品技术援助有限公司 检测针对抗-TNFα药物的自身抗体的测定法
BR112013028808A2 (pt) 2011-05-10 2016-09-06 Nestec Sa métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada
CN103782172A (zh) 2011-07-06 2014-05-07 雀巢产品技术援助有限公司 检测针对使用TNFα的生物疗法的中和性自体抗体的测定法
US20140017174A1 (en) * 2011-11-30 2014-01-16 Raja Atreya Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
MX352118B (es) 2012-03-08 2017-11-09 Hoffmann La Roche Metodo de inmunoanalisis cromatografico multiplexado para la caracterizacion de inmunocomplejos circulantes.
US20130295685A1 (en) * 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
US10132736B2 (en) * 2012-05-24 2018-11-20 Abbvie Inc. Methods for inspection of protein particles in a liquid beneficial agent
KR101501375B1 (ko) 2012-09-21 2015-03-10 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
WO2014046474A2 (ko) * 2012-09-21 2014-03-27 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
MX358730B (es) 2012-10-05 2018-09-03 Nestec Sa Metodos para predecir y monitorear cicatrizacion de la mucosa.
BR112015012482A2 (pt) * 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
AP2015008879A0 (en) * 2013-05-16 2015-11-30 Univ Pretoria A method of diagnosing tuberculosis
EP3077538A1 (en) 2013-12-03 2016-10-12 Nestec S.A. Signaling pathways in tissues from inflammatory bowel disease patients
WO2015083087A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Methods for predicting post-operative recurrence of crohn's disease
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
EP3210027B1 (en) 2014-10-20 2019-04-17 Nestec S.A. Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
EP3227685A1 (en) 2014-12-02 2017-10-11 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
MX2017007232A (es) 2014-12-05 2017-10-16 Nestec Sa Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.
US11085931B2 (en) 2015-01-09 2021-08-10 W. Health L.P. Universal assay for determining the quantity of TNFα inhibitory drugs and their corresponding anti-drug-antibodies
WO2016135707A1 (en) 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
ES2815224T3 (es) 2015-11-06 2021-03-29 Promise Proteomics Un método para cuantificar anticuerpos terapéuticos
ES2716900T3 (es) * 2015-11-06 2019-06-17 Promise Advanced Proteomics Un método para cuantificar anticuerpos anti-TNF
WO2017201142A1 (en) * 2016-05-17 2017-11-23 Memorial Sloan Kettering Cancer Center Treatment of lung adenocarcinoma
WO2018007327A1 (en) * 2016-07-08 2018-01-11 Atonomics A/S A universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples
EP3695229A1 (en) 2017-10-10 2020-08-19 Prometheus Biosciences, Inc. Methods for monitoring vedolizumab treatment
EP3514541A1 (de) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
US11225516B2 (en) * 2018-04-20 2022-01-18 Janssen Biotech, Inc. Transition analysis method for chromatography column qualification
JP2022522816A (ja) * 2019-03-04 2022-04-20 アムジエン・インコーポレーテツド 高分子量種のインビボでの可逆性
KR102562006B1 (ko) 2020-11-09 2023-08-02 바디텍메드(주) 항tnf-알파 약물 모니터링을 위한 신속 검출 키트

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US4459359A (en) 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4857456A (en) 1985-04-30 1989-08-15 The Regents Of The University Of California Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders
FR2590674B1 (fr) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
EP0440044A1 (en) 1990-01-31 1991-08-07 Abbott Laboratories Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing
US5094740A (en) 1990-02-16 1992-03-10 Glycomed, Inc. Two-dimensional electrophoretic separation of carbohydrates
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5582998A (en) 1991-06-19 1996-12-10 Boehringer Ingelheim International Gmbh Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
JPH0566222A (ja) 1991-09-09 1993-03-19 Tosoh Corp 物質の分析方法
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
JPH07110331A (ja) * 1993-09-07 1995-04-25 Wako Pure Chem Ind Ltd ヒト補体価測定方法及びヒト補体価測定用試薬組成物
ES2150970T3 (es) 1993-09-07 2000-12-16 Wako Pure Chem Ind Ltd Procedimiento y reactivo para la medida de la actividad del complemento.
JPH07140144A (ja) 1993-11-19 1995-06-02 S R L:Kk アレルゲン特異的ＩｇＥ抗体の測定方法および抗原抗体複合体の測定方法
DK0800578T3 (da) * 1994-12-28 2003-08-11 Univ Kentucky Rekombinant monoklonalt anti-idiotype antistof 3H1
HU230515B1 (hu) * 1996-02-09 2016-10-28 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazásai
DE69740016D1 (de) 1996-08-12 2010-11-18 Sekisui Chemical Co Ltd BEHäLTER UND KITS ZUR BESTIMMUNG VON ZELLFUNKTIONEN UND VERFAHREN ZU DEREN BESTIMMUNG
JP3718435B2 (ja) * 1996-08-12 2005-11-24 積水化学工業株式会社 細胞機能測定用容器及び細胞機能測定方法
US6391622B1 (en) 1997-04-04 2002-05-21 Caliper Technologies Corp. Closed-loop biochemical analyzers
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
WO2000026394A1 (en) * 1998-10-31 2000-05-11 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Variants of humanized anti-carcinoma monoclonal antibody cc49
DE19858777B4 (de) * 1998-12-18 2006-07-27 Delta Biotechnology Ltd. Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
AU776395B2 (en) * 1999-12-06 2004-09-09 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Aminobenzophenones as inhibitors of IL-1beta and TNF-alpha
EP1238077A1 (en) 1999-12-16 2002-09-11 Amgen Inc., Tnfr/opg-like molecules and uses thereof
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP1370867B1 (en) 2001-03-02 2010-08-04 Activx Biosciences, Inc. Protein profiling platform
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003016909A1 (en) 2001-08-16 2003-02-27 Ludwig Institute For Cancer Research Method for determining protein component in a biological sample
DE60236536D1 (de) 2001-11-12 2010-07-08 Merck Patent Gmbh Modifizierter anti-tnf antikörper
IL158297A0 (en) 2001-12-05 2004-05-12 Cangene Corp Pharmaceutical compositions containing immune globulin and methods for the preparation thereof
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
EP1542722A4 (en) 2002-08-01 2006-02-01 Wyeth Corp METHOD AND REAGENTS RELATED TO INFLAMMATION AND APOPTOSIS
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7648825B2 (en) 2003-06-20 2010-01-19 University Of Florida Research Foundation, Inc. Biomarkers for differentiating between type 1 and type 2 diabetes
NZ545221A (en) * 2003-08-01 2009-09-25 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
JP2007528868A (ja) 2003-08-14 2007-10-18 ワイス 抗ルイスｙ抗イディオタイプ抗体およびその使用
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
CA2572263A1 (en) 2004-06-30 2006-01-12 Centocor, Inc. Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
RU2007147426A (ru) 2005-05-20 2009-06-27 Дженентек, Инк. (Us) Предварительная обработка биологического образца, взятого у индивидуума с аутоиммунным заболеванием
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
ES2530265T3 (es) 2005-07-21 2015-02-27 Genmab A/S Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
EP1937307A4 (en) 2005-09-14 2009-05-13 Hutchinson Fred Cancer Res SPECIFIC ELIMINATION OF ACTIVATED IMMUNE CELLS
US7542502B2 (en) 2005-09-27 2009-06-02 Cymer, Inc. Thermal-expansion tolerant, preionizer electrode for a gas discharge laser
CA2626859A1 (en) * 2005-11-08 2007-05-18 Medarex, Inc. Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
JP2007147367A (ja) 2005-11-25 2007-06-14 Sekisui Chem Co Ltd サイトカイン産生能の測定方法
DE102005057920A1 (de) 2005-12-02 2007-06-28 Strohner, Pavel, Dr. Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben
WO2008008349A2 (en) 2006-07-11 2008-01-17 Drexel University Methods of quantitatively assessing inflammation with biosensing nanoparticles
US20080286774A1 (en) 2007-05-16 2008-11-20 The Regents Of The University Of California Real-time individualized therapy evaluation
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
EP2200613B1 (en) * 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
EP2240769A1 (en) * 2008-01-15 2010-10-20 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
JP2011513753A (ja) 2008-03-05 2011-04-28 シンギュレックス・インコーポレイテッド 分子の高感度検出の方法および組成物
RU2015148676A (ru) 2009-10-26 2019-01-15 Нестек С.А. Способы выявления препаратов и аутоантител против tnf
SG189391A1 (en) 2010-10-18 2013-05-31 Nestec Sa Methods for determining anti-drug antibody isotypes
CN103502815B (zh) 2011-02-17 2015-09-23 雀巢产品技术援助有限公司 检测针对抗-TNFα药物的自身抗体的测定法
US20130266963A1 (en) 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
CN103782172A (zh) 2011-07-06 2014-05-07 雀巢产品技术援助有限公司 检测针对使用TNFα的生物疗法的中和性自体抗体的测定法
US20130295685A1 (en) 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
US20140051184A1 (en) 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
BR112015012482A2 (pt) 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
MX2017007232A (es) 2014-12-05 2017-10-16 Nestec Sa Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.

Also Published As

Publication number Publication date
US10386366B2 (en) 2019-08-20
CN104634955B (zh) 2016-09-14
AU2015202899A1 (en) 2015-06-18
US8574855B2 (en) 2013-11-05
CN102695955B (zh) 2015-03-18
NZ621655A (en) 2015-08-28
RU2015148676A (ru) 2019-01-15
EP2494352A1 (en) 2012-09-05
ES2796530T3 (es) 2020-11-27
KR101881714B1 (ko) 2018-07-24
RU2015148676A3 (es) 2019-06-18
JP5697677B2 (ja) 2015-04-08
IL219315B (en) 2018-01-31
WO2011056590A1 (en) 2011-05-12
US20170184588A1 (en) 2017-06-29
US20150024404A1 (en) 2015-01-22
IL256728A (en) 2018-04-09
AU2015202899B2 (en) 2017-06-01
AU2010315547A1 (en) 2012-05-10
KR101761541B1 (ko) 2017-07-26
RU2571489C2 (ru) 2015-12-20
JP6082831B2 (ja) 2017-02-15
KR20170088437A (ko) 2017-08-01
ZA201203717B (en) 2018-11-28
AU2019205009A1 (en) 2019-08-01
RU2012121710A (ru) 2013-12-10
AU2010315547B2 (en) 2015-03-05
JP2015148616A (ja) 2015-08-20
JP2013508739A (ja) 2013-03-07
CA3108458A1 (en) 2011-05-12
CA2778454A1 (en) 2011-05-12
US20140057367A1 (en) 2014-02-27
AU2010315547C1 (en) 2015-06-04
US20120329172A1 (en) 2012-12-27
US20200018751A1 (en) 2020-01-16
KR20120108978A (ko) 2012-10-05
US8865417B2 (en) 2014-10-21
CN104634955A (zh) 2015-05-20
JP2016106222A (ja) 2016-06-16
NZ706187A (en) 2016-09-30
EP2494352B1 (en) 2020-04-08
CN102695955A (zh) 2012-09-26
MX2012004877A (es) 2012-05-23
IL219315A0 (en) 2012-06-28
AU2017213584A1 (en) 2017-08-31
AU2017213584B2 (en) 2019-04-18
JP5878253B2 (ja) 2016-03-08
CA2778454C (en) 2021-03-02
US9506920B2 (en) 2016-11-29
ZA201504548B (en) 2019-10-30
BR112012009855A2 (pt) 2018-06-26
NZ599456A (en) 2014-06-27

Similar Documents

Publication Publication Date Title
MX343328B (es) Analisis para la deteccion de farmacos anti-tnf y anticuerpos.
MX349561B (es) Método para detectar nucleosomas que contienen variantes de histonas.
TR201904386T4 (tr) Nükleotidleri içeren nükleozomların saptanmasına yönelik yöntem.
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
BR112013020981A2 (pt) ensaios para a detecção de auto-anticorpos para os fármacos anti-tnf<244>
ATE472110T1 (de) Sensoreinrichtung und verfahren zur erfassung von magnetischen teilchen
EP3264090A3 (en) Method for detecting nucleosome adducts
CO6680668A2 (es) Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor
MX343324B (es) Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
IN2015DN01855A (es)
MX2013013986A (es) Deteccion rapida de actividad metabolica.
WO2011144948A3 (en) Detecting descented material
EA201291396A1 (ru) Способ детекции молекулярных взаимодействий
MX2015006852A (es) Ensayos para detectar autoanticuerpos neutralizantes para terapia biologica.
MX2012014096A (es) Métodos para mejorar el diagnóstico de enfermedad intestinal inflamatoria.
GB201206977D0 (en) An enzyme detection device
MX2012009908A (es) Ensayos y equipos para la serotipificacion de pseudomas aeruginosa y secuencias de oligonucleotido utiles en dichos metodos y equipos.
FR2953292B1 (fr) Capteur d'hydrogene et procede de detection d'une concentration en hydrogene.
BRPI1009573A2 (pt) método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente.
MX2016005313A (es) Deteccion de la actividad de corte de una enzima.
SG10201806729VA (en) Novel assay to detect human periostin
GB2470757B (en) Non invasive gas analysis
WO2011085057A3 (en) Methods for detecting insulin autoantibody
WO2012083492A8 (en) Methods of cationic polymer detection
GB201314219D0 (en) Fluid collection and expulsion apparatus